Latest National Institute of Neurological Disorders and Stroke Stories
MIDDLETOWN, Ohio, May 7 /PRNewswire-USNewswire/ -- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease.
--Modified Cells Disrupt Signal Control, May Permit Seizures-- PHILADELPHIA AND BOSTON, April 26, /PRNewswire-USNewswire/ -- Neuroscience researchers have zeroed in on a novel mechanism that helps control the firing of electrical signals among neurons.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Results reflect extraordinary efforts of physicians and scientists, and success at obtaining stimulus dollars, in increasingly tough funding climate ANN ARBOR, Mich., April 9 /PRNewswire-USNewswire/ -- University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health (NIH) research funding in federal fiscal year 2009, according to NIH data.
MENLO PARK, Calif., Feb. 18 /PRNewswire/ -- SRI International, an independent nonprofit research and development institute, announced today that a new Neurodegenerative Diseases Research Program has been established within its Center for Health Sciences.
Health care research got a boost on Monday by way of President Barack Obamaâ€™s proposed budget, with the National Institutes of Health in line for $1 billion earmarked for medical research.
Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use.
Researchers have developed an improved version of an enzyme that degrades the dense scar tissue that forms when the central nervous system is damaged.
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass, are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability.
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc.
- A poem in which the author retracts something said in an earlier poem.